Novel statistical tools for monitoring the safety of marketed drugs.
about
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionStatin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting systemFactors Affecting the Timing of Signal Detection of Adverse Drug ReactionsStandardizing adverse drug event reporting dataNovel data-mining methodologies for adverse drug event discovery and analysisInformation technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectivesComparison of two drug safety signals in a pharmacovigilance data mining framework.Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.Data mining of the public version of the FDA Adverse Event Reporting SystemUsing aggregated, de-identified electronic health record data for multivariate pharmacosurveillance: a case study of azathioprine.Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases.Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases.Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age StratificationMining pharmacovigilance data using Bayesian logistic regression with James-Stein type shrinkage estimation.Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting SystemAspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Similarity-based modeling applied to signal detection in pharmacovigilance.Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithmThe upper bound to the Relative Reporting Ratio-a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection.Mining adverse drug reactions from online healthcare forums using hidden Markov modelAutomatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives.Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.Using information mining of the medical literature to improve drug safety.Biclustering of adverse drug events in the FDA's spontaneous reporting system.Use of the self-controlled case series method in drug safety assessmentSGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactionsNovel opportunities for computational biology and sociology in drug discovery
P2860
Q27335410-4E6D753A-935B-4CA0-BD08-AA8175C76BF9Q28478481-1655F0C3-B915-43BD-9929-67B20ADEBD49Q28551405-8A87344B-2451-4624-9A87-FF3B1E1D91A9Q28654311-3FA32F5F-9E4B-4BC5-9B3A-A46706B9A50EQ28681788-49F2EC5F-6E1F-46BA-8B30-BE761FECE372Q28743950-5B20B595-CBC3-42B0-A083-717CFA147C68Q30573571-A8CC912B-6747-43D2-9C05-C7BC0CFB8119Q30622918-84045EF1-6643-414F-A5D4-09A56EE205E3Q30651235-87CFE286-42AA-4E8D-83E0-E9788CB2F043Q30687155-69A34A40-F902-4631-BB38-81193F7A2C64Q30790443-709D2842-A258-46AD-9783-A128D399DE1CQ30803396-EF8E7471-68BF-45DC-B4C0-872D2D00261FQ31040399-146039D3-D9C1-4442-B105-624C397E9B54Q31144205-765782CD-8022-4F7E-AF18-2B6BA473C4DCQ33363061-794A79CB-CBFF-4C67-A936-CAD230E6AD1CQ33397057-4CBBD543-533F-4757-A315-66165B57F8E1Q33398998-148B39BE-C55F-4159-B40C-3C11DEEC291EQ33422275-E61C1012-899D-48BE-9D4C-4B7DBBBDBDA5Q33432682-B3152E7C-1EDE-4393-A1E5-724F9473D8CEQ33664885-5011B84B-EF4B-40BE-8D46-D85CBAE96F17Q33681951-14ECF06E-6157-4A41-B5E6-CBED8DAFD1DCQ33911016-2B192966-EA7A-4C6E-AAF9-765451B42CE3Q33912042-027B1316-8839-4B9B-82B4-8596F715ECB1Q34039745-2B6BFD14-471E-4890-BB22-C8FD9109C57CQ34320987-15AB956A-4E42-4218-AEEE-8BEDDB179E18Q34364050-B44B3A3C-A823-4FEF-AC83-45F0759D4EF6Q34381979-AE563A15-C448-4CC0-BCE4-02C8C2DE187AQ34413023-21C27369-DCD7-442A-B014-28A05A13F0DBQ34584149-623566E4-B2E3-40EE-9DB2-92D45B5FE41FQ34693736-D5E7DF63-B275-4B4D-911B-901F1D29B86DQ34699150-7E79EBA8-863F-4A85-BF31-0ACB7F643D97Q34812232-D90FBCC2-D58C-419C-A6BD-D82FB81156BFQ34881857-829B59B9-1963-48CD-B9B7-B14FC65567CEQ35069176-F3095F65-62E3-4CBD-B1EB-C9E6C97A911BQ35200247-9CEB7C23-CDAB-4ADD-A1FA-6EB0F09DB607Q35764731-0D2B8076-A50A-4527-AE4D-169AB183B78EQ36204221-5AF0473B-B09B-4FAF-A4BF-5CE45BDD44A4Q36370828-B1129BD1-3518-449B-9FD0-A662EA5A4157Q36771112-335F1038-00A8-47B9-A91F-F7A5EFB7D9CEQ36845732-B01CD952-8BBB-4FD0-B50A-08012ED0F323
P2860
Novel statistical tools for monitoring the safety of marketed drugs.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Novel statistical tools for monitoring the safety of marketed drugs.
@en
type
label
Novel statistical tools for monitoring the safety of marketed drugs.
@en
prefLabel
Novel statistical tools for monitoring the safety of marketed drugs.
@en
P2093
P356
P1476
Novel statistical tools for monitoring the safety of marketed drugs.
@en
P2093
E N Pattishall
J S Almenoff
S J W Evans
W DuMouchel
P304
P356
10.1038/SJ.CLPT.6100258
P407
P577
2007-05-30T00:00:00Z